Merck Discontinues Nemtabrutinib Clinical Development Program
Merck discontinued the clinical development program evaluating nemtabrutinib (MK-1026), an investigational BTK inhibitor.
Merck discontinued the clinical development program evaluating nemtabrutinib (MK-1026), an investigational BTK inhibitor.